Wockhardt

Wockhardt gets US FDA nod to market Ceftazidime injections

16 Oct 2008

Lintas Bangalore bags Wockhardt account

13 Oct 2008

Wockhardt says derivative losses not to affect Q1 performance

24 Mar 2008

Wockhardt's Azithromycin to battle Pfizer's Zithromax in the US market

13 Feb 2008

Wockhardt to demerge R&D business

18 Jan 2008

Wockhardt enters billion-dollar anti-allergic Zyrtec market in the US

02 Jan 2008

Wockhardt gets US FDA nod to enter the $2.6 billion Norvasc market

By | 17 Sep 2007

Wockhardt to introduce treatment for dermatological scars

17 Apr 2007

The bigger picture

04 Apr 2007

What the benefactors say

04 Apr 2007

Wockhardt receives US FDA approval for diuretic injection

28 Mar 2007

FDA orders withdrawal of Wockhardt's insulin brand 'Wosulin'

25 Nov 2006

Wockhardt Q3 net up 14 per cent at Rs74 crore, sales up 22 per cent at Rs438 crore

26 Oct 2006

Wockhardt acquires Pinewood for $150 million, fourth European acquisition

By | 03 Oct 2006

Wockhardt to develop SEZ near Aurangabad for its global biopharma hub

18 Sep 2006

Wockhardt's Cefotaxime injection receives US FDA approval

31 Aug 2006

Wockhardt UK expanding Byetta manufacturing capacity

16 Jun 2006

Wockhardt gets US FDA approval for anti-epilepsy drug

14 Jun 2006

Wockhardt in-licenses dermatology drug from LSI of UK

05 Jun 2006

Wockhardt receives US FDA approval for clarithromycin tablets

01 Jun 2006

US FDA approves Wockhardt's Waluj plant

By | 11 May 2006

Wockhardt to raise up to $800 million to fund overseas acquisitions

16 Mar 2006

Huzaifa Khorakiwala Dr Murtaza Khorakiwala join Wockhardt board

By | 16 Mar 2006

Wockhardt amongst first to receive US FDA approval for Zonisamide Capsules

26 Dec 2005

Wockhardt becomes South Asia''s first JCI-accredited super-speciality hospital

11 Nov 2005